Disorat
Disorat - General Information
A beta-adrenergic antagonist effective for both beta-1 and beta-2 receptors. It is used as an antiarrhythmic, antihypertensive, and antiglaucoma agent. [PubChem]
Pharmacology of Disorat
Disorat is a beta1 and beta2 (non-selective) adrenergic receptor-blocking agent that does not have significant intrinsic sympathomimetic, direct myocardial depressant, or local anesthetic (membrane-stabilizing) activity. Disorat is indicated in the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma. Disorat, when applied topically to the eye, has the action of reducing elevated, as well as normal, intraocular pressure, whether or not accompanied by glaucoma. Elevated intraocular pressure is a major risk factor in the pathogenesis of glaucomatous visual field loss and optic nerve damage. Disorat reduces intraocular pressure with little or no effect on pupil size or accommodation in contrast to the miosis which cholinergic agents are known to produce.
Disorat for patients
Tell your doctor if you have: asthma, heart disease, lung disease, thyroid disease, diabetes, muscle disease, any allergies. Vision may be temporarily blurred or unstable for a period after applying eye drops. Use caution if driving or performing duties requiring clear vision. This medication should be used only if clearly needed during pregnancy or while breast-feeding. Discuss the risks and benefits with your doctor.
Disorat Interactions
OptiPranolol Ophthalmic Solution should be used with caution in patients who are receiving a beta-adrenergic blocking agent orally, because of the potential for additive effects on systemic beta-blockade.
Close observation of the patient is recommended when a beta-blocker is administered to patients receiving catecholamine-depleting drugs such as reserpine, because of possible additive effects and the production of hypotension and/or bradycardia.
Caution should be used in the coadministration of beta-adrenergic receptor blocking agents, such as metipranolol, and oral or intravenous calcium channel antagonists, because of possible precipitation of left ventricular failure, and hypotension. In patients with impaired cardiac function, who are receiving calcium channel antagonists, coadministration should be avoided.
The concomitant use of beta-adrenergic receptor blocking agents with digitalis and calcium channel antagonists may have additive effects, prolonging atrioventricular conduction time.
Caution should be used in patients using concomitant adrenergic psychotropic drugs.
Ocular
In patients with angle-closure glaucoma, the immediate treatment objective is to re-open the angle by constriction of the pupil with a miotic agent. OptiPranolol Ophthalmic Solution has little or no effect on the pupil, therefore, when it is used to reduce intraocular pressur e in angle-closure glaucoma, it should be used only with concomitant administration of a miotic agent.
Disorat Contraindications
Hypersensitivity to any component of this product.
OptiPranolol Ophthalmic Solution is contraindicated in patients with bronchial asthma or a history of bronchial asthma, or severe chronic obstructive pulmonary disease; symptomatic sinus bradycardia; greater than a first degree atrioventricular block; cardiogenic shock; or overt cardiac failure.
Additional information about Disorat
Disorat Indication: Indicated in the treatment of elevated intraocular pressure in patients with ocular hypertension or open angle glaucoma.
Mechanism Of Action: Although it is known that metipranolol binds the beta1 and beta2 adrenergic receptors, the mechanism of metipranolol's action is not known. It has no significant intrinsic sympathomimetic activity, and has only weak local anesthetic (membrane-stabilizing) and myocardial depressant activity. It appears that the ophthalmic beta-adrenergic blocking agents reduce aqueous humor production, as demonstrated by tonography and fluorophotometry. A slight increase in aqueous humor outflow may be an additional mechanism.
Drug Interactions: Not Available
Food Interactions: Not Available
Generic Name: Metipranolol
Synonyms: Metipranololum [Inn-Latin]; Metipranolol hydrochloride
Drug Category: Adrenergic beta-Antagonists; Sympatholytics; Antihypertensive Agents; Anti-Arrhythmia Agents
Drug Type: Small Molecule; Approved
Other Brand Names containing Metipranolol: Disorat; Trimepranol; OptiPranolol;
Absorption: Not Available
Toxicity (Overdose): Not Available
Protein Binding: Not Available
Biotransformation: Not Available
Half Life: Not Available
Dosage Forms of Disorat: Solution / drops Ophthalmic
Chemical IUPAC Name: [4-[2-hydroxy-3-(propan-2-ylamino)propoxy]-2,3,6-trimethylphenyl] acetate
Chemical Formula: C17H27NO4
Metipranolol on Wikipedia: https://en.wikipedia.org/wiki/Metipranolol
Organisms Affected: Humans and other mammals